These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 30064098)

  • 1. Carboplatin as an alternative to Cisplatin in chemotherapies: New insights at single molecule level.
    Oliveira L; Caquito JM; Rocha MS
    Biophys Chem; 2018 Oct; 241():8-14. PubMed ID: 30064098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Force spectroscopy unravels the role of ionic strength on DNA-cisplatin interaction: Modulating the binding parameters.
    Oliveira L; Rocha MS
    Phys Rev E; 2017 Sep; 96(3-1):032408. PubMed ID: 29346883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
    Knox RJ; Friedlos F; Lydall DA; Roberts JJ
    Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.
    Parker RJ; Gill I; Tarone R; Vionnet JA; Grunberg S; Muggia FM; Reed E
    Carcinogenesis; 1991 Jul; 12(7):1253-8. PubMed ID: 2070490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin- and carboplatin-DNA adducts: is PT-AG the cytotoxic lesion?
    Fichtinger-Schepman AM; van Dijk-Knijnenburg HC; van der Velde-Visser SD; Berends F; Baan RA
    Carcinogenesis; 1995 Oct; 16(10):2447-53. PubMed ID: 7586150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplatin ineffectiveness against cancer from a molecular perspective: A single-molecule force-spectroscopy study.
    Oliveira L; Caquito JM; Rocha MS
    Phys Rev E; 2020 Jun; 101(6-1):062412. PubMed ID: 32688610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raman spectroscopic evaluation of DNA adducts of a platinum containing anticancer drug.
    Jangir DK; Mehrotra R
    Spectrochim Acta A Mol Biomol Spectrosc; 2014 Sep; 130():386-9. PubMed ID: 24810023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding.
    Bloemink MJ; Reedijk J
    Met Ions Biol Syst; 1996; 32():641-85. PubMed ID: 8640534
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin.
    Hongo A; Seki S; Akiyama K; Kudo T
    Int J Biochem; 1994 Aug; 26(8):1009-16. PubMed ID: 8088411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
    Mandal R; Kalke R; Li XF
    Chem Res Toxicol; 2004 Oct; 17(10):1391-7. PubMed ID: 15487901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biophysical characterization of the DNA interaction with the biogenic polyamine putrescine: A single molecule study.
    Publio BC; Moura TA; Lima CHM; Rocha MS
    Int J Biol Macromol; 2018 Jun; 112():175-178. PubMed ID: 29414728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of caffeine on the structure and conformation of DNA: A force spectroscopy study.
    Moura TA; Oliveira L; Rocha MS
    Int J Biol Macromol; 2019 Jun; 130():1018-1024. PubMed ID: 30844457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic insight from kinetic studies on the interaction of model palladium (II) complexes with nucleic acid components.
    Rau T; van Eldik R
    Met Ions Biol Syst; 1996; 32():339-78. PubMed ID: 8640525
    [No Abstract]   [Full Text] [Related]  

  • 15. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
    Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
    Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry.
    Hah SS; Stivers KM; de Vere White RW; Henderson PT
    Chem Res Toxicol; 2006 May; 19(5):622-6. PubMed ID: 16696564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The kinetics and mechanisms of the reaction of Mesna with cisplatin, oxiplatin and carboplatin.
    Oprea A; Bazzazi H; Kangarloo B; Wolff JE
    Anticancer Res; 2001; 21(2A):1225-9. PubMed ID: 11396168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA-cisplatin interaction studied with single molecule stretching experiments.
    Crisafuli FA; Cesconetto EC; Ramos EB; Rocha MS
    Integr Biol (Camb); 2012 May; 4(5):568-74. PubMed ID: 22513758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs.
    Theile D; Kos M
    Toxicol Lett; 2016 Feb; 242():47-52. PubMed ID: 26656794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation of platinum-DNA adducts in pediatric patients receiving carboplatin.
    Tonda ME; Murry DJ; Rodman JH
    Pharmacotherapy; 1996; 16(4):631-7. PubMed ID: 8840369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.